Cite
Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients.
MLA
Ng, Chee C., et al. “Mechanism-Based Receptor-Binding Model to Describe the Pharmacokinetic and Pharmacodynamic of an Anti-Α5β1 Integrin Monoclonal Antibody (Volociximab) in Cancer Patients.” Cancer Chemotherapy & Pharmacology, vol. 65, no. 2, Jan. 2010, pp. 207–17. EBSCOhost, https://doi.org/10.1007/s00280-009-1023-8.
APA
Ng, C. C., Bai, S., Takimoto, C. H., Tang, M. T., & Tolcher, A. W. (2010). Mechanism-based receptor-binding model to describe the pharmacokinetic and pharmacodynamic of an anti-α5β1 integrin monoclonal antibody (volociximab) in cancer patients. Cancer Chemotherapy & Pharmacology, 65(2), 207–217. https://doi.org/10.1007/s00280-009-1023-8
Chicago
Ng, Chee C., S. Bai, C. H. Takimoto, M. T. Tang, and A. W. Tolcher. 2010. “Mechanism-Based Receptor-Binding Model to Describe the Pharmacokinetic and Pharmacodynamic of an Anti-Α5β1 Integrin Monoclonal Antibody (Volociximab) in Cancer Patients.” Cancer Chemotherapy & Pharmacology 65 (2): 207–17. doi:10.1007/s00280-009-1023-8.